epileptic.qol


The SANAD (Standard and New Antiepileptic Drugs) study (Marson et al., 2007)
is a randomised control trial of standard and new antiepileptic drugs,
comparing effects on longer term clinical outcomes. Quality of life (QoL)
data were collected by mail at baseline, 3 months, and at 1 and 2 years using
validated measures. This data is a subset of the trial for 544 patients
randomised to one of 2 drugs: carbamazepine and lamotrigine.


data

Fits the joint model proposed by Henderson and colleagues (2000)
<doi:10.1093/biostatistics/1.4.465>, but extended to the case of multiple
continuous longitudinal measures. The time-to-event data is modelled using a
Cox proportional hazards regression model with time-varying covariates. The
multiple longitudinal outcomes are modelled using a multivariate version of the
Laird and Ware linear mixed model. The association is captured by a multivariate
latent Gaussian process. The model is estimated using a Monte Carlo Expectation
Maximization algorithm. This project is funded by the Medical Research Council
(Grant number MR/M013227/1).

Graeme L. Hickey

joineRML

Joint Modelling of Multivariate Longitudinal Data and
Time-to-Event Outcomes

epileptic.qol function

A data frame with 1853 observations on the following 9 variables:
  <dl> </dl>

Format

SANAD Trial: University of Liverpool. See Jacoby et al. (2015).

epileptic.qol: Quality of life data following epilepsy drug treatment

Description

Usage

Arguments

Format

Source

References

See Also